Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Adebrelimab Plus Apatinib for BCLC Stage C HCC
NCT06482008Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06482008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482008.